3 Drug Stocks to Buy at a Discount

Novo Nordisk won approval for a GLP-1 oral pill expected to launch in early 2026, potentially reshaping the competitive landscape that saw Eli Lilly overtake Novo Nordisk with more attractive GLP-1 injections. The piece highlights investor opportunities in large-cap drugmakers coping with upcoming patent cliffs and pipeline gaps: Pfizer (yield 6.8%, payout ratio >100%, shares down >50% from highs) has pursued acquisitions and partnerships to rebuild its GLP-1 pipeline; Bristol Myers Squibb (yield 4.6%, payout ratio ~85%, shares down ~30%) has used acquisitions to bolster its pipeline despite Revlimid/Pomalyst patent losses; and Merck (yield 3.2%, payout ratio ~45%, shares off ~20%) benefits from Keytruda patents that extend domestically to 2028 and internationally into the early 2030s. For allocators, the note frames these names as contrarian, income- and value-oriented plays while flagging execution and patent-timing risk that could pressure near-term fundamentals.

Analysis

Market structure: Oral GLP‑1 approval (NVO) materially reallocates optionality between delivery formats — winners are NVO (oral adoption), LLY (injectable market share/efficacy leader), and contract manufacturers that scale sterile injectables; losers are smaller injectables-only entrants and mid‑cap specialty rivals facing payer compression. Expect accelerated demand expansion for the class (addressable patient base +20–50% over 2–3 years) but rising price pressure as payers push step therapy, which could compress prices by an estimated 10–30% in the most exposed molecules over 12–24 months.

Risk assessment: Tail risks include a class safety signal or restrictive reimbursement policy (Medicare formulary or US price negotiation) that could knock 30–60% off market expectations; immediate headline risk can move individual tickers ±10–25% intradays. Time windows: days—news-driven volatility; months—market share shifts as oral rollout begins (early 2026); years—patent cliffs (BMY/PFE/MRK between 2026–2028+) and potential lifecycle extensions. Hidden dependencies: China approvals/partnerships (PFE), sterile manufacturing capacity, and payer coverage decisions drive real uptake, not just FDA labeling.

Trade implications: Implement size‑limited, differentiated positions: favor MRK for yield/resilience and LLY for GLP‑1 execution; de‑weight PFE/BMY relative to peers given dividend sustainability and imminent patent exposure. Use options to express asymmetric views: buy long‑dated NVO/LLY call exposure around the 2026 launch window while hedging with short dated puts around patent/catalyst dates. Rotate sector exposure from high‑yield cyclicals into R&D‑rich large caps (increase biotech/large‑cap pharma allocation by 3–5% funded from underperforming dividend names).

Contrarian angles: The market may be overpaying for NVO’s headline (pill) while underpricing Merck’s Keytruda franchise extensions; oral adoption could be slower because efficacy and cost may favor injectables for many patients — NVO upside is binary to commercial uptake. Historical parallel: rapid initial excitement (e.g., first‑in‑class drugs) often gives way to payer control and price compression; prepare for a multi‑year trade where execution and reimbursement matter more than FDA headlines.

Key Decisions for Investors

• Establish a 2–3% long position in MRK for capital preservation and yield (3.0–3.5%) targeting total return if Keytruda extensions hold to 2028+; add on >5% pullback. Monitor quarterly revenue for Keytruda and international patent filings through 2026; trim if FCF margin drops >200 bps YoY.
• Initiate a 1–2% core long in LLY to play injectable GLP‑1 leadership; complement with a directional LEAP call (expire Jan‑2027) sized to 0.5–1% notional, preferably 20–30% OTM, to capture 출시/market‑share upside around early‑2026. Reduce exposure if market share falls below 30% vs class within 12 months.
• Open a 1–2% net short or underweight in PFE (or long MRK/PFE pair) due to payout ratio >100% and pipeline setbacks; hedge dividend risk by buying a 6–12 month put (size 0.5% notional) or short near‑term bonds of PFE if yield curve and credit widen. Exit or reverse if PFE announces accretive M&A or FCF recovery that lowers payout ratio below 80%.
• Buy protection for exposed names (BMY/PFE) with 6–12 month puts sized to 1% notional to hedge patent cliff risk; alternatively sell covered calls on MRK to harvest yield if implied volatility rises >25% ahead of catalyst dates. Reassess after Novo pill commercial uptake metrics (prescriptions/month and payer coverage) reported in first two quarters post‑launch (target H1‑2026).